This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock VACC vs. SLN, ALMS, LFVN, SLS, LRMR, ENTA, SPRO, ALDX, IMAB, and EPRXShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Silence Therapeutics (SLN), Alumis (ALMS), LifeVantage (LFVN), SELLAS Life Sciences Group (SLS), Larimar Therapeutics (LRMR), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), Aldeyra Therapeutics (ALDX), I-Mab (IMAB), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Its Competitors Silence Therapeutics Alumis LifeVantage SELLAS Life Sciences Group Larimar Therapeutics Enanta Pharmaceuticals Spero Therapeutics Aldeyra Therapeutics I-Mab Eupraxia Pharmaceuticals Silence Therapeutics (NASDAQ:SLN) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends. Do analysts rate SLN or VACC? Silence Therapeutics currently has a consensus target price of $33.83, suggesting a potential upside of 534.77%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Silence Therapeutics is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, SLN or VACC? Silence Therapeutics has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Is SLN or VACC more profitable? Silence Therapeutics has a net margin of -342.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-342.00% -62.81% -33.89% Vaccitech -409.18%-23.41%-20.85% Does the MarketBeat Community believe in SLN or VACC? Silence Therapeutics received 30 more outperform votes than Vaccitech when rated by MarketBeat users. Likewise, 78.33% of users gave Silence Therapeutics an outperform vote while only 70.83% of users gave Vaccitech an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes4778.33% Underperform Votes1321.67% VaccitechOutperform Votes1770.83% Underperform Votes729.17% Which has stronger valuation & earnings, SLN or VACC? Vaccitech has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$27.70M5.76-$53.82M-$1.50-3.55Vaccitech$13.42M2.59$5.34M-$1.43-0.63 Does the media prefer SLN or VACC? In the previous week, Silence Therapeutics had 8 more articles in the media than Vaccitech. MarketBeat recorded 8 mentions for Silence Therapeutics and 0 mentions for Vaccitech. Silence Therapeutics' average media sentiment score of 0.73 beat Vaccitech's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silence Therapeutics Positive Vaccitech Neutral Do institutionals and insiders believe in SLN or VACC? 98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Vaccitech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySilence Therapeutics beats Vaccitech on 12 of the 18 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.82M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-0.638.5026.7819.65Price / Sales2.59263.11404.49152.18Price / Cash19.3065.8538.2534.64Price / Book0.146.526.964.59Net Income$5.34M$143.48M$3.23B$248.23M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.90-1.2%N/A-51.9%$34.82M$13.42M-0.6333Gap UpSLNSilence Therapeutics2.8439 of 5 stars$5.50+1.7%$33.83+515.2%-73.0%$164.62M$27.70M-3.50100News CoveragePositive NewsAnalyst ForecastGap DownALMSAlumis2.8554 of 5 stars$3.41-1.2%$24.86+628.9%N/A$161.02M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionLFVNLifeVantage3.9842 of 5 stars$12.70-1.2%$30.50+140.2%+68.0%$159.87M$222.35M22.68260Positive NewsSLSSELLAS Life Sciences Group0.3671 of 5 stars$1.60-2.4%N/A+14.5%$159.64M$1M-2.3210News CoverageShort Interest ↑LRMRLarimar Therapeutics2.5257 of 5 stars$2.45+1.7%$19.67+702.7%-70.3%$156.87MN/A-2.1330Short Interest ↓Gap DownENTAEnanta Pharmaceuticals3.7014 of 5 stars$7.11-1.1%$18.00+153.2%-44.2%$151.99M$64.46M-1.44160Positive NewsAnalyst DowngradeSPROSpero Therapeutics3.8122 of 5 stars$2.66+0.8%$5.00+88.0%+106.6%$148.72M$28.30M38.01150Short Interest ↑Gap DownHigh Trading VolumeALDXAldeyra Therapeutics2.8496 of 5 stars$2.47+5.1%$9.50+284.6%-28.0%$147.94MN/A-2.5515IMABI-Mab3.081 of 5 stars$1.79-4.3%$5.50+207.3%+33.9%$146.17M$3.27M0.00380News CoverageGap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2874 of 5 stars$3.97-2.5%$10.50+164.5%+39.9%$142.32MN/A-5.5129 Related Companies and Tools Related Companies Silence Therapeutics Competitors Alumis Competitors LifeVantage Competitors SELLAS Life Sciences Group Competitors Larimar Therapeutics Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Aldeyra Therapeutics Competitors I-Mab Competitors Eupraxia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VACC Stock Free VACC Stock Alerts